Axovant Orphan Drug Designation

AXOVANT GENE THERAPIES RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR AXO-AAV-GM1 FOR THE TREATMENT OF GM1 GANGLIOSIDOSIS NEW YORK and BASEL, Switzerland, Nov. 18, 2019 (GLOBE NEWSWIRE) — Axovant Gene Therapies Ltd. (NASDAQ: AXGT), a clinical-stage company...